{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:57:20Z","timestamp":1793642240592,"version":"4.5.1"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Ruxolitinib is a selective JAK1\/2 inhibitor, and its application in treating adult-onset dermatomyositis(DM) has rarely been described. Here, we report a case of an adult-onset DM patient with anti-TIF1\u03b3 antibody, who also suffered from essential thrombocytosis related to the <jats:italic>JAK2 V617F<\/jats:italic> mutation. Her clinical symptoms of DM markedly improved after ruxolitinib treatment, whereas her platelet count did not significantly change. In addition, we reviewed previous studies on the treatment of adult DM with ruxolitinib, and summarized reports of the J<jats:italic>AK2 V617F<\/jats:italic> mutation in adult idiopathic inflammatory myopathy.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1591631","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T05:21:18Z","timestamp":1749705678000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Ruxolitinib in adult dermatomyositis with anti-TIF1\u03b3 antibody: a case report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Xu","family":"Jing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Shanshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41392-024-01934-w","article-title":"The JAK-STAT pathway: from structural biology to cytokine engineering","volume":"9","author":"Lv","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead404","article-title":"Tofacitinib therapy in refractory inflammatory myositis: a retrospective cohort study of 41 patients","volume":"63","author":"Beckett","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-024-05551-2","article-title":"Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease","volume":"44","author":"Harada","year":"2024","journal-title":"Rheumatol Int"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003837","article-title":"Upadacitinib therapy in refractory inflammatory myositis: a case series of 10 patients","volume":"10","author":"Beckett","year":"2024","journal-title":"RMD Open"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2401488","DOI":"10.1183\/13993003.01488-2024","article-title":"Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multi-center cohort study","volume":"65","author":"Wu","year":"2025","journal-title":"Eur Respir J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-624536","article-title":"JAK2V617F complete molecular remission in polycythemia vera\/essential thrombocythemia patients treated with ruxolitinib","volume":"125","author":"Pieri","year":"2015","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-785790","article-title":"Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide","volume":"130","author":"Harrison","year":"2017","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.nmd.2019.10.005","article-title":"239th ENMC international workshop: classification of dermatomyositis, amsterdam, the Netherlands, 14\u201316 december 2018","volume":"30","author":"Mammen","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1412997","article-title":"Remission of recalcitrant dermatomyositis treated with ruxolitinib","volume":"371","author":"Hornung","year":"2014","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"adv00144","DOI":"10.2340\/00015555-3481","article-title":"Unexpected hair regrowth in a patient with longstanding alopecia universalis during treatment of recalcitrant dermatomyositis with the janus kinase inhibitor ruxolitinib","volume":"100","author":"Fetter","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2020.02.015","article-title":"Severe MDA5 dermatomyositis associated with cancer and controlled by JAK inhibitor","volume":"41","author":"Jalles","year":"2020","journal-title":"Rev Med Interne"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.10.055","article-title":"JAK inhibitors for the treatment of adult dermatomyositis: A pilot study","volume":"88","author":"Landon-Cardinal","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2023.09.043","article-title":"Efficacy of topical ruxolitinib for cutaneous dermatomyositis","volume":"45","author":"Lanis","year":"2023","journal-title":"JAAD Case Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy105","article-title":"JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis","volume":"141","author":"Ladislau","year":"2018","journal-title":"Brain"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.4940","article-title":"Ruxolitinib for refractory PL-12 antisynthetase syndrome-associated angioedema-like panniculitis with clonal T-cell receptor gene rearrangement","volume":"160","author":"Sengupta","year":"2024","journal-title":"JAMA Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05286-y","article-title":"The relationship between JAK2(V617F) mutation and dermatomyositis-a case report and literature review","volume":"40","author":"Xu","year":"2021","journal-title":"Clin Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.09.020","article-title":"JAK-STAT signaling pathway, immunodeficiency, inflammation, immune dysregulation, and inborn errors of immunity","volume":"155","author":"Samra","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41408-019-0236-2","article-title":"Myelofibrosis in 2019: moving beyond JAK2 inhibition","volume":"9","author":"Schieber","year":"2019","journal-title":"Blood Cancer J"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2023.11.019","article-title":"Features of immune mediated diseases in JAK2 (V617F)-positive myeloproliferative neoplasms and the potential therapeutic role of JAK inhibitors","volume":"123","author":"\u00c1lvarez-Reguera","year":"2024","journal-title":"Eur J Intern Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/art.41602","article-title":"Study of tofacitinib in refractory dermatomyosits: an open-label pilot study of ten patients","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218690","article-title":"Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis","volume":"80","author":"Kim","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/art.42846","article-title":"Risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors in cardiovascular risk-enriched rheumatoid arthritis patients","volume":"76","author":"Charles-Schoeman","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222543","article-title":"Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomized controlled ORAL Surveillance trial","volume":"82","author":"Curtis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224049","article-title":"JAK inhibitors and the risk of Malignancy: a meta-analysis across disease indications","volume":"82","author":"Russell","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01045-w","article-title":"International guideline for idiopathic inflammatory myopathy-associated cancer screening: an international myositis assessment and clinical studies group (IMACS) initiative","volume":"19","author":"Oldroyd","year":"2023","journal-title":"Nat Rev Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1591631\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T05:21:19Z","timestamp":1749705679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1591631\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":25,"alternative-id":["10.3389\/fimmu.2025.1591631"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1591631","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"article-number":"1591631"}}